Abstract:Abstract Despite a recent explosion of approved drugs for IBD that primarily target cytokines and T-cell trafficking, therapeutic response rates remain low (30-50 %), underscoring the need for more efficacious treatments with fewer side effects. From a drug development perspective, it takes over 10 years for a new drug to reach the market with >90% attrition rates. The realization that drug testing in animal models does not always translate to humans, particularly for complex diseases of high heterogeneity like IBD, leaving a significant gap in pre-clinical drug evaluation. Technologies such as organoids or “gut on a chip” attempted to fulfill this gap, but among their limitations are lack of tissue complexity and an externally induced, and often biased, “disease state” that fails to capture patient heterogeneity and underlying disease mechanisms. We developed a Therapeutic Response Predictor Assay for IBD (TheRPA _ibd) which is based on establishing short term explant cultures from the patient’s diseased tissue (PDE). PDEs can be treated with various candidate drugs or their combinations and inform whether an individual patient is a responder or non-responder to the particular treatment. TheRPA_ibd has been clinically validated for anti-TNF with a predictive accuracy of 0.87 (p<0.0001). TheRPA_ibd was used to comparatively evaluate 6 JAK inhibitors (JAKi) with different JAK isoform selectivity (tofacitinib, baricitinib, upadacitinib, ritlecitinib, filgotinib, and peficitinib). PDEs were derived from mucosal inflamed biopsies obtained during colonoscopy or surgical resection (26 CD/11 UC). JAKi responses were evaluated using targeted and bulk gene expression, antibody arrays and multiplex ELISA. Our analysis, in addition to previously described cytokines, identified several chemokines as downstream targets of JAK inhibition: CXCL1; CXCL2; CXCL3; CXCL5; CXCL8; CXCL9; CXCL10; CXCL11; CXCL16; CCL10; CCL20. Of clinical importance, interrogation of publicly available gene expression IBD datasets confirmed a robust dysregulation of those targets in both UC and CD. Such findings open new avenues for exploring chemokine-driven pathways as potential therapeutic targets in IBD and potentially additional inflammatory conditions. From a mechanistic perspective, JAK1 or JAK3 selective inhibitors appeared to lack broader cytokine and chemokine inhibition compared to pan-JAKi. Notably, as a target, TYK2 was found to be critical for maximizing the anti-inflammatory effects of JAKi. The PDE-based assay (TheRPA) not only enables selection of patient-tailored treatments but also as a “clinical trial in a dish” platform can efficiently contribute to candidate drug de-risking and prioritization. As a proof of concept, using this technology we have been able to demonstrate efficacy in CD of certain JAK inhibitors prior to their FDA approval for this indication.

Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

CRISPR/Cas9-targeting of CD40 in Hematopoietic Stem Cells Limits Immune Activation Mediated by Anti-Cd40

Validation of a CRISPR/cas9-based technology platform for examining specific immune gene functions in an experimental murine model of IBD

A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis

Chimeric and mutant CARD9 constructs enable analyses of conserved and diverged autoinhibition mechanisms in the CARD-CC protein family

A Functional Genomics Predictive Network Model Identifies Regulators of Inflammatory Bowel Disease

CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

OP08 Multi-ancestry genome-wide association study of inflammatory bowel disease identifies 125 novel loci and directly implicates new genes in disease susceptibility

Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases

[Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators]

Translational genetics identifies a phosphorylation switch in CARD9 required for innate inflammatory responses

Drug Repositioning of Inflammatory Bowel Disease Based on Co-Target Gene Expression Signature of Glucocorticoid Receptor and TET2

DISEASE MODELING IN INFLAMMATORY BOWEL DISEASE (IBD) USING PATIENT-DERIVED EXPLANTS (PDE) REVEALS CHEMOKINES AS A RELEVANT TARGET OF JAK INHIBITION

Functional screen of inflammatory bowel disease genes reveals key epithelial functions

Pathway paradigms revealed from the genetics of inflammatory bowel disease

Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis

Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease